Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Reviewing Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME)
04:32am, Monday, 17'th Nov 2025
Zymeworks (NYSE: ZYME - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two c
Zymeworks (NASDAQ:ZYME) and Addex Therapeutics (OTCMKTS:ADDXF) Head to Head Survey
03:44am, Saturday, 15'th Nov 2025
Addex Therapeutics (OTCMKTS:ADDXF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies ba
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
12:06am, Friday, 07'th Nov 2025
Zymeworks Inc. ( ZYME ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Shrinal Inamdar - Director of Investor Relations Leone Patterson - Executive VP and Chief Business & Fin
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
06:36pm, Thursday, 06'th Nov 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.39 per share a year ago.
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC Conference First patient dosed in Phase 1 clinical trial of Z
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Thursday, 30'th Oct 2025
Zymeworks (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Thursday
02:09am, Thursday, 30'th Oct 2025
Zymeworks (NYSE: ZYME - Get Free Report) is anticipated to issue its results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.28) per share an
Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 29'th Oct 2025
Zymeworks (ZYME) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 28'th Oct 2025
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
09:47pm, Thursday, 23'rd Oct 2025
Zymeworks Inc. (NASDAQ:ZYME ) Shareholder/Analyst Call October 23, 2025 3:30 PM EDT Company Participants Sabeen Mekan - Senior Vice President of Clinical Development Stuart Barnscher Conference Call P
VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. $ZYME Position Trimmed by KLP Kapitalforvaltning AS
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS trimmed its holdings in shares of Zymeworks Inc. (NYSE: ZYME) by 29.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional inv
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade
10:55am, Thursday, 16'th Oct 2025
The mean of analysts' price targets for Zymeworks (ZYME) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
06:00am, Thursday, 16'th Oct 2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
